Noesis Capital Mangement Corp reduced its stake in shares of Bristol-Myers Squibb Company (NYSE:BMY) by 33.3% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 6,769 shares of the biopharmaceutical company’s stock after selling 3,372 shares during the quarter. Noesis Capital Mangement Corp’s holdings in Bristol-Myers Squibb were worth $377,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently modified their holdings of BMY. Blue Chip Partners Inc. lifted its stake in Bristol-Myers Squibb by 0.7% in the second quarter. Blue Chip Partners Inc. now owns 2,156 shares of the biopharmaceutical company’s stock worth $120,000 after acquiring an additional 15 shares during the period. Jackson Grant Investment Advisers Inc. lifted its stake in Bristol-Myers Squibb by 0.4% in the second quarter. Jackson Grant Investment Advisers Inc. now owns 3,905 shares of the biopharmaceutical company’s stock worth $218,000 after acquiring an additional 15 shares during the period. Keel Point LLC lifted its stake in Bristol-Myers Squibb by 0.3% in the first quarter. Keel Point LLC now owns 6,286 shares of the biopharmaceutical company’s stock worth $342,000 after acquiring an additional 18 shares during the period. Shayne & CO. LLC lifted its stake in Bristol-Myers Squibb by 0.6% in the second quarter. Shayne & CO. LLC now owns 4,041 shares of the biopharmaceutical company’s stock worth $225,000 after acquiring an additional 24 shares during the period. Finally, Chilton Investment Co. LLC lifted its stake in Bristol-Myers Squibb by 0.5% in the second quarter. Chilton Investment Co. LLC now owns 5,283 shares of the biopharmaceutical company’s stock worth $294,000 after acquiring an additional 26 shares during the period. 69.69% of the stock is owned by hedge funds and other institutional investors.

In other news, SVP Joseph C. Caldarella sold 9,340 shares of the company’s stock in a transaction dated Wednesday, September 6th. The shares were sold at an average price of $60.00, for a total transaction of $560,400.00. Following the transaction, the senior vice president now owns 46,297 shares in the company, valued at $2,777,820. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 0.23% of the company’s stock.

Bristol-Myers Squibb Company (NYSE BMY) opened at $62.90 on Thursday. The company has a market cap of $102,326.49, a PE ratio of 21.12, a price-to-earnings-growth ratio of 2.37 and a beta of 1.18. The company has a quick ratio of 1.46, a current ratio of 1.59 and a debt-to-equity ratio of 0.47. Bristol-Myers Squibb Company has a fifty-two week low of $46.01 and a fifty-two week high of $66.10.

Bristol-Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 EPS for the quarter, missing the Zacks’ consensus estimate of $0.77 by ($0.02). The firm had revenue of $5.25 billion during the quarter, compared to the consensus estimate of $5.20 billion. Bristol-Myers Squibb had a return on equity of 32.41% and a net margin of 20.56%. The business’s revenue for the quarter was up 6.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.77 earnings per share. equities analysts predict that Bristol-Myers Squibb Company will post 2.99 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Wednesday, November 1st. Shareholders of record on Friday, October 6th were issued a $0.39 dividend. The ex-dividend date of this dividend was Thursday, October 5th. This represents a $1.56 dividend on an annualized basis and a yield of 2.48%. Bristol-Myers Squibb’s dividend payout ratio is presently 61.42%.

A number of analysts recently weighed in on the stock. Vetr lowered shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating and set a $64.20 price objective for the company. in a research note on Tuesday, August 22nd. Citigroup set a $72.00 price objective on shares of Bristol-Myers Squibb and gave the stock a “buy” rating in a research note on Wednesday, October 25th. BMO Capital Markets set a $49.00 price objective on shares of Bristol-Myers Squibb and gave the stock a “sell” rating in a research note on Thursday, October 26th. Credit Suisse Group set a $58.00 price objective on shares of Bristol-Myers Squibb and gave the stock a “hold” rating in a research note on Wednesday, August 16th. Finally, Cowen set a $65.00 price objective on shares of Bristol-Myers Squibb and gave the stock a “hold” rating in a research note on Monday, August 14th. One equities research analyst has rated the stock with a sell rating, ten have issued a hold rating and eleven have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $64.93.

ILLEGAL ACTIVITY WARNING: “Bristol-Myers Squibb Company (BMY) Stake Lessened by Noesis Capital Mangement Corp” was originally published by Daily Political and is the property of of Daily Political. If you are accessing this report on another domain, it was illegally stolen and republished in violation of international copyright legislation. The correct version of this report can be read at https://www.dailypolitical.com/2017/11/30/bristol-myers-squibb-company-bmy-stake-lessened-by-noesis-capital-mangement-corp.html.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.